hotspot -WSS

hotspot

author：hotspot 2025-09-30 21:22:37 - browse：91

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： With trial win, GSK could get blood cancer drug back on market

WSS

Poland's lawmakers approve a divisive law on Russian influence

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

BMI, flaws aside, is found to be useful estimate of body fat in youth

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: Palliative care found as helpful given virtually as in person

Doctors increasingly discourage vaping amid mounting health concerns

Wikipedia

hotspot

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Shifting the focus from loneliness to social health

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ultragenyx gene therapy for rare liver ailment succeeds in late

New air purifier tech could be key to improving indoor air quality

Doctors in states that ban abortion can still help patients

Apple is now the first public company to be valued at $3 trillion

House GOP plan to stem drug shortages differs from Democrats’

After affirmative action ruling, medical educators look to 'holistic review'

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

hotspot

Russian and Belarusian players banned from a women's tennis tournament in Prague

Adidas to release second batch of Yeezy sneakers after breakup with Ye

American TikTok star stuck in Dubai for months following rental car altercation

Campaign finance charge dropped from case against Sam Bankman

ASCO: AstraZeneca says CAR

Europe is fastest

focus

focus

leisure time

hotspot